Pediatric Neurology
Volume 34, Issue 2 , Pages 106-109 , February 2006

Botulinum Toxin Type A for the Treatment of the Spastic Equinus Foot in Cerebral Palsy

Received 1 March 2005 ,Accepted 11 August 2005.

References 

  1. Kim IW , Han TR , Bang MS , Lim JY , Yoon BH . Risk factors of cerebral palsy in preterms infants . Am J Phys Rehabil . 2002;81:297–303
  2. Simpson DM . Clinical trials of botulinum toxin in the treatment of spasticity . Muscle Nerve . 1997;6(Suppl.):S169–S175
  3. Cardoso E , Rodrigues B , Lucena R , Oliveira IR , Pedreira G , Melo A . Botulinum toxin type A for the treatment of the upper limb spasticity after stroke (A meta-analysis) . Arq Neuropsiquiatr . 2005;63:30–33
  4. Olney SJ , Wright MJ . Cerebral palsy . In:  Campbell SK editors. Physical therapy for children . Philadelphia: Saunders; 1995;p. 489–524
  5. Graham HK , Aoki KR , Autti-Ramo I , et al.   Recommendations for the use of botulinum toxin type A in the management of cerebral palsy . Gait Posture . 2000;11:67–79
  6. Jadad AR , Moore A , Carrol D . Assessing the quality of reports of randomised clinical trials (Is blinding necessary?) . Controlled Clinical Trials . 1996;17:1–12
  7. Baker R , Jasinski M , MaciagTymecka I , et al.   Botulinum toxin treatment of spasticity in diplegic cerebral palsy (A randomized, double-blind, placebo-controlled, dose-ranging study) . Dev Med Child Neurol . 2002;44:666–675
  8. Koman LA , Mooney JF , Smith BP , Goodman A , Mulvaney T . Management of cerebral palsy with botulinum-A toxin (Report of a preliminary, randomized, double-blind trial) . J Pediatr Orthop . 1994;14:299–303
  9. Koman LA , Mooney JF , Smith BP , Walker F , Leon JM . Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy (A randomized, double-blind, placebo-controlled trial) . J Pediatr Orthop . 2000;20:108–115
  10. Love SC , Valentine JP , Blair EM , Price CJ , Cole JH , Chauvel PJ . The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia (A randomized controlled trial) . Eur J Neurol . 2001;8(Suppl. 5):50–58
  11. Sutherland DH , Kaufman KR , Wyatt MP , Chambers HG , Mubarak SJ . Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy . Gait Posture . 1999;10:1–9
  12. Ubhi T , Bhakta BB , Ives HL , Allgar V , Roussounis SH . Randomized double blind placebo controlled trial of the effects of botulinum toxin on walking in cerebral palsy . Arch Dis Child . 2000;83:481–487
  13. Koman L , Smith BP , Shilt JS . Cerebral palsy . Lancet . 2004;363:1619–1628
  14. Pidcock FS . The emerging role of therapeutic botulinum toxin in the treatment of cerebral palsy . J Pediatr . 2004;145:S33–S35
  15. Bakheit AM . Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticity . J Neurol Neurosurg Psychiatry . 2004;75:665–666
  16. Melo A , Gabriele AP , Rodrigues B , et al.   Consenso sobre uso de toxina botulínica na paralisia cerebral . ABPC . 2005;1:18–25

PII: S0887-8994(05)00481-9

doi: 10.1016/j.pediatrneurol.2005.08.010

Pediatric Neurology
Volume 34, Issue 2 , Pages 106-109 , February 2006

Article Tools

* Image Usage & Resolution